格隆汇1月19日丨三博脑科(301293.SZ)在投资者互动平台表示，公司是以神经专科为特色的医疗服务集 团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的 研发、生产及销售。前期投资认购的北脑一期基金的投资领域将主要投资于新一代用于脑科疾病检查诊 断、治疗等领域的医疗器材、耗材及药物等。 ...

北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会的 法律意见 二〇二六年一月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会的 法律意见 致：三博脑科医院管理集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受三博脑科医院管理集团股份 有限公司（以下简称"公司"）委托，指派本所律师列席公司 2026 年第一次临时 股东会（以下简称"本次股东会"），并出具本法律意见 ...

特别提示： 三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301293 证券简称：三博脑科 公告编号：2026-003 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 2、会议召开的合法、合规性：本次股东会的召开符合有关法律、行政法规、 部门规章、规范性文件及《公司章程》的规定。 3、会议召开时间： （1）现场会议时间：2026 年 1 月 16 日下午 15:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2026 年 1 月 16 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为：2026 年 1 月 16 日 9:15-15:00 期间的任意时间。 4、会议召开方式：现场投票与网络投票相结合的方式。 5、现场会议召开地点：北京市海淀区世纪金源香山商旅酒店 831 栋公司会 议室 （一）会议召开情况 ...

（文章来源：证券日报） 证券日报网讯 1月15日，三博脑科在互动平台回答投资者提问时表示，目前公司财务部门正在核算2025 年度的财务数据，如触及披露标准，公司将按规定在指定媒体公开披露，请留意公司的公告。 ...

Core Viewpoint - Sanbo Brain Science (301293.SZ) is making progress in its brain-computer interface (BCI) business, but its main revenue still comes from high-end neurosurgery services, with BCI technology currently contributing minimally to overall performance [2]. Group 1: Surgical Trials - The company has completed one interventional brain-computer interface surgery at its Fujian branch, with no other surgeries reported within the group [2]. Group 2: External Investment and Collaboration - Sanbo Brain Science has previously invested in three brain science funds and has established a joint research center for precision medicine in collaboration with Tsinghua University’s School of Biomedical Engineering [2]. - Ongoing projects related to these collaborations are still in progress [2]. Group 3: Revenue Impact - The revenue generated from the company's neuromodulation technology is currently very small, having a negligible impact on the company's overall performance [2].

Core Viewpoint - Sanbo Neuroscience (301293.SZ) is a medical service group specializing in neurology, primarily providing advanced neurosurgical services, with current revenue from neuromodulation technology being minimal and not significantly impacting overall performance [1] Company Overview - The company operates as a specialized medical service group focused on neurology [1] - Its main facilities offer comprehensive medical services centered around high-end neurosurgery [1] Revenue Insights - Revenue generated from neuromodulation technology constitutes a small portion of the company's total revenue [1] - The impact of this revenue stream on the company's overall performance is negligible [1]

Group 1 - The main market saw a net inflow of 19.18 billion yuan as of January 14 [1] - The top ten sectors with the largest capital outflows included Energy Metals (-1.365 billion yuan), Wind Power Equipment (-1.086 billion yuan), and Communication Equipment (-0.983 billion yuan) [1] - The banking sector experienced a capital outflow of 0.721 billion yuan, while the healthcare services sector saw an outflow of 0.628 billion yuan [1] Group 2 - The Energy Metals sector had a slight decline of 0.13% with a net outflow of 1.365 billion yuan, led by the company Greenmei [2] - The Wind Power Equipment sector increased by 1.61% but still faced a net outflow of 1.086 billion yuan, with major outflow attributed to Daikin Heavy Industries [2] - The Communication Equipment sector rose by 4.01% despite a net outflow of 0.983 billion yuan, primarily driven by Galaxy Electronics [2][3]

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Group 1 - The Chinese government has adjusted the export tax rebate policy for photovoltaic and battery products, reducing the VAT export rebate rate for battery products from 9% to 6% starting April 1, 2026, and fully canceling it by January 1, 2027, with a three-month transition period [2] - The purpose of the policy adjustment is to compress the profit margins of low-value-added production, encourage companies to transition to high-value-added products, and guide enterprises to establish overseas production to mitigate geopolitical risks [2][3] - The lithium carbonate futures market has seen a significant increase, with the main contract closing at 156,060 yuan per ton, marking a 9% increase and the first time surpassing the 150,000 yuan mark in two years, driven by policy changes and improved fundamentals [2] Group 2 - In the photovoltaic sector, companies are expected to accelerate order deliveries during the transition period, leading to a significant increase in export growth in the first quarter of 2026, particularly benefiting leading companies with high export ratios [3] - From 2027 onwards, industry differentiation is expected to intensify, with overseas production capacity becoming a core competitive advantage for leading companies like CATL, BYD, and LONGi, as domestic production costs will rise by 6-9% due to the cancellation of tax rebates [3] - The exit of outdated production capacity is anticipated to significantly increase industry concentration, with the top five companies expected to exceed 80% market share by 2027, enhancing pricing power and overall profitability in the industry [3] Group 3 - The Federal Reserve Chairman Jerome Powell is under criminal investigation related to the renovation of the Federal Reserve's headquarters, which has escalated tensions with former President Trump, who has previously criticized Powell for not lowering interest rates [4][5] - Powell described the investigation as unprecedented and questioned its motives, asserting that he would not succumb to political pressure while fulfilling his duties [4][5][7] Group 4 - Gold and silver prices have surged, with gold surpassing $4,600 and silver exceeding $83, driven by increased geopolitical risks and expectations of interest rate cuts following poor non-farm payroll data [8][9] - The U.S. government is considering various options to intervene in Iran, including military actions, which has contributed to rising demand for safe-haven assets like gold [8][9] Group 5 - ByteDance has significantly increased its investment in data centers, with a capital expenditure budget of approximately 160 billion yuan for 2025, including nearly 70 billion yuan specifically for data center infrastructure and network equipment [10][11] - The bidding activity for AI data centers has accelerated, with major projects like a 1 GW project already announced, indicating a robust demand surge starting in the fourth quarter of 2025 [11][14] - The improvement in AI chip supply, particularly the easing of export restrictions on NVIDIA's H200 chips, has facilitated the resumption of data center construction plans that were previously hindered by chip shortages [12][15] Group 6 - The domestic AI data center bidding landscape is expected to benefit from the scarcity of resources, with operators possessing high-quality resources having a stronger ability to fulfill orders and maintain pricing power [19] - The preference for bidding is concentrated in regions with lower electricity costs, such as Inner Mongolia and Shanxi, which will significantly reduce operational costs for data centers [19] - The domestic liquid cooling sector is poised for recovery as demand from AI data centers exceeds expectations, benefiting local manufacturers closely tied to major internet companies [18]

Group 1: Market Trends and Developments - The brain-computer interface (BCI) sector is transitioning from clinical validation to commercial scalability, with 2026 expected to be a pivotal year for industrialization [2] - China's BCI market is projected to grow from 3.2 billion yuan in 2024 to 5.58 billion yuan in 2027, reflecting a compound annual growth rate of approximately 20% [2] - Global BCI market is anticipated to exceed 40 billion USD by 2030 [2] Group 2: Company Innovations and Collaborations - Yingkang Life has developed a comprehensive management solution for Parkinson's treatment using BCI technology, having completed over 20 deep brain stimulation surgeries [2] - Cheng Yi Tong's recent patent for "brainwave acquisition devices" is expected to enhance its core technology and market share in the BCI field [3] - Entropy Technology plans to launch a prototype BCI product by March 2026, focusing on commercial applications [3] - Yingqu Technology collaborates with various partners to develop BCI-related products, including brainwave monitoring headbands and rehabilitation robots [4] - Hanwei Technology has made breakthroughs in non-invasive flexible BCI materials, although commercial applications remain uncertain [5] - Daoshi Technology has strategically invested in Qiangnao Technology to enhance its capabilities in BCI applications across medical rehabilitation and education [6] - Sanbo Brain Science is advancing its "North Brain No. 2" project, focusing on flexible microelectrode technology for clinical applications [7] - Meihua Medical is a strategic partner in the cochlear implant sector, which is a significant application of BCI technology [7] Group 3: Investment and Strategic Partnerships - Leidi Ke has acquired a 20.41% stake in Aoyi Technology, which specializes in both BCI and robotics, enhancing its capabilities in the medical and health sectors [9] - Lihua Science and Technology's subsidiary, Weiling Medical, is developing a fully implanted wireless BCI system [10] - Guiyan Biotech is exploring precious metal materials for BCI applications, with some products in the experimental stage [11]